MX2020004148A - Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf). - Google Patents

Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf).

Info

Publication number
MX2020004148A
MX2020004148A MX2020004148A MX2020004148A MX2020004148A MX 2020004148 A MX2020004148 A MX 2020004148A MX 2020004148 A MX2020004148 A MX 2020004148A MX 2020004148 A MX2020004148 A MX 2020004148A MX 2020004148 A MX2020004148 A MX 2020004148A
Authority
MX
Mexico
Prior art keywords
raf kinase
crystalline salts
kinase inhibitor
inhibitor
crystalline
Prior art date
Application number
MX2020004148A
Other languages
English (en)
Inventor
Bodo Betzemeier
Ulrike Werthmann
Otmar Schaaf
Gerd Michael Maier
Original Assignee
Xynomic Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xynomic Pharmaceuticals Inc filed Critical Xynomic Pharmaceuticals Inc
Publication of MX2020004148A publication Critical patent/MX2020004148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con sales cristalinas de N-(3-(5-((1-etilpiperidin-4-il)(metil)amino)- 3-(pirimidin-5-il)-1H-pirrolo[3,2-b]piridin-1-il)-2,4- difluorofenil)propano-1-sulfonamida, un inhibidor de la cinasa RAF, útiles en el tratamiento del cáncer y otras enfermedades.
MX2020004148A 2017-10-26 2018-10-26 Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf). MX2020004148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577313P 2017-10-26 2017-10-26
PCT/US2018/057792 WO2019084459A1 (en) 2017-10-26 2018-10-26 CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR

Publications (1)

Publication Number Publication Date
MX2020004148A true MX2020004148A (es) 2022-09-09

Family

ID=64277870

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004148A MX2020004148A (es) 2017-10-26 2018-10-26 Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf).

Country Status (14)

Country Link
US (2) US11306086B2 (es)
EP (2) EP4245758A3 (es)
JP (2) JP7230041B2 (es)
KR (1) KR20200088345A (es)
CN (2) CN116942672A (es)
AU (2) AU2018355528B2 (es)
BR (1) BR112020008248A2 (es)
CA (1) CA3080324A1 (es)
ES (1) ES2947411T3 (es)
IL (1) IL274027B2 (es)
MX (1) MX2020004148A (es)
PH (1) PH12020550485A1 (es)
SG (1) SG11202003635TA (es)
WO (1) WO2019084459A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008248A2 (pt) 2017-10-26 2020-10-20 Xynomic Pharmaceuticals, Inc. sais cristalinos de um inibidor da quinase b-raf
JP2022069426A (ja) * 2020-10-23 2022-05-11 マイラン ラボラトリーズ リミテッド テネリグリプチン２．５臭化水素酸塩のアモルファスを調製する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
WO2005047289A1 (en) * 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
NZ565255A (en) 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
PE20121025A1 (es) * 2009-09-28 2012-08-06 Hoffmann La Roche Compuestos de benzoxazepina como inhibidores de la p13k
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
TWI589576B (zh) 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
ES2978957T3 (es) 2015-04-16 2024-09-23 Nitto Denko Corp Agente inductor de muerte celular para células que tienen mutación en el gen BRAF, agente para inhibir la proliferación de dichas células y composición farmacéutica para tratar a un paciente que padece efectos de proliferación anómala de dichas células
CN105801584B (zh) * 2016-03-16 2019-03-05 中国药科大学 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途
BR112020008248A2 (pt) 2017-10-26 2020-10-20 Xynomic Pharmaceuticals, Inc. sais cristalinos de um inibidor da quinase b-raf

Also Published As

Publication number Publication date
AU2018355528B2 (en) 2021-11-18
US11306086B2 (en) 2022-04-19
IL274027B1 (en) 2023-08-01
WO2019084459A1 (en) 2019-05-02
US20220204506A1 (en) 2022-06-30
CN111818924A (zh) 2020-10-23
ES2947411T3 (es) 2023-08-08
JP7230041B2 (ja) 2023-02-28
EP3700530A1 (en) 2020-09-02
RU2020116763A3 (es) 2022-04-29
IL274027B2 (en) 2023-12-01
CA3080324A1 (en) 2019-05-02
EP4245758A2 (en) 2023-09-20
AU2022201044B2 (en) 2023-07-13
US11753409B2 (en) 2023-09-12
US20200283433A1 (en) 2020-09-10
EP3700530B1 (en) 2023-04-19
BR112020008248A2 (pt) 2020-10-20
JP2023062074A (ja) 2023-05-02
SG11202003635TA (en) 2020-05-28
AU2018355528A1 (en) 2020-05-07
EP4245758A3 (en) 2023-12-20
CN116942672A (zh) 2023-10-27
JP2021501199A (ja) 2021-01-14
PH12020550485A1 (en) 2021-03-22
KR20200088345A (ko) 2020-07-22
CN111818924B (zh) 2023-08-15
RU2020116763A (ru) 2021-11-26
AU2022201044A1 (en) 2022-03-10
IL274027A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
CY1123796T1 (el) Στερεες μορφες μιας ενωσης που τροποποιει κινασες
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
BR112015021995A2 (pt) combinações de inibidores de tirosina quinase de bruton e inibidores de cyp3a4
SA520411638B1 (ar) Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
MY192059A (en) Heterocyclic amides as kinase inhibitors
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
EA201591255A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
EA201792116A1 (ru) Ингибитор янус-киназы
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
ZA202204284B (en) Inhibitors of raf kinases
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
MX2018004332A (es) Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
EA201891772A1 (ru) Трифторацетатная соль агониста tlr7 и ее кристаллическая форма b, способы получения и использование
BR112017007545A2 (pt) derivados de carbazol
TR201909353T4 (tr) Multipl skleroz tedavisi.